CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C, Yin S, To KKW, Fu L. · 2023
Read CD39/CD73/A2AR pathway and cancer immunotherapy. by Xia C, Yin S, To KKW, Fu L. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9979453.txt.
Description
Xia and co-authors review the CD39/CD73/A2AR pathway in cancer immunotherapy. Tumors build a suppressive setting that blunts immune attack. Two surface enzymes, CD39 and CD73, convert ATP into adenosine step by step. Built-up adenosine then signals through its receptors.
The A2A receptor drives strong immune suppression through cAMP signaling. Blocking this pathway could restore antitumor immunity. Antibodies and small-molecule blockers are now in clinical trials. They are tested alone and with anti-PD-1 or anti-PD-L1 drugs. The review covers pathway roles in growth, spread, and drug resistance. It also discusses markers to pick patients for such treatment. The authors frame the pathway as a way around immunotherapy resistance.
Catalog record
| CREATOR | Xia C, Yin S, To KKW, Fu L. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |